A Study of Injectable BLB101 and Blincyto® in Adult Participants With R/R CD19+ B-ALL

NCT07723911 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

212

Enrollment

OTHER

Sponsor class

Conditions

Precursor B-cell Acute Lymphoblastic Leukemia

Interventions

DRUG: BLB101 for Injection
DRUG: Blinatumomab for Injection

Sponsor

Institute of Hematology & Blood Diseases Hospital, China